Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Fujimoto, Daichi; Yoshioka, Hiroshige; Kataoka, Yuki; Morimoto, Takeshi; Kim, Young Hak; Tomii, Keisuke; Ishida, Tadashi; Hirabayashi, Masataka; Hara, Satoshi; Ishitoko, Manabu; Fukuda, Yasushi; Hwang, Moon Hee; Sakai, Naoki; Fukui, Motonari; Nakaji, Hitoshi; Morita, Mitsunori; Mio, Tadashi; Yasuda, Takehiro; Sugita, Takakazu; Hirai, Toyohiro

doi:10.1016/j.lungcan.2018.02.017

Cited by 124 publications

(107 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with poor ECOG PS showed reduced effectiveness. The association of ECOG PS has been reported in multiple previous studies, and the result in the present study was consistent with these reports among PS 0, 1 vs PS 2, or 2 and worse [17,20]. However, this study showed clear benefit in OS and PFS even between PS 0 and PS 1.…”

Section: Effectivenesssupporting

confidence: 93%

See 1 more Smart Citation

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Morita¹,

Okishio

Shimizu

et al. 2020

Lung Cancer

Self Cite

View full text Add to dashboard Cite

Section: Effectivenesssupporting

confidence: 93%

“…Approximately 20 % of the patients treated were 75 years of age or older, and approximately 25 % of patients were ECOG PS ≥ 2, which is comparable figures as reported in other retrospective studies conducted in Japan [17].…”

Section: Patients and Treatment Patternssupporting

confidence: 86%

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Morita¹,

Okishio

Shimizu

et al. 2020

Lung Cancer

Self Cite

View full text Add to dashboard Cite

“…11 In NSCLC, Fujimoto et al showed the ORRs were higher in patients with ILD than in those without (37% vs. 18%, respectively) and the PFS was significantly longer (5.8 vs. 2.1 months, respectively; P = 0.002). 15 We also found a positive correlation between the development of ILD and clinical efficacy. Moreover, we report the details and risk factors of ILD.…”

Section: Discussionsupporting

confidence: 58%

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research the features and risk factors of ILD in advanced non‐small cell lung cancer (NSCLC). Methods Between December 2015 and November 2018, 130 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non‐irAEs group). Subsequently, we divided the irAEs group into two groups based on the incidence of ILD (ILD group and irAEs‐non‐ILD group). Treatment efficacy and the characteristics of ILD were evaluated. Results A total of 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had a higher objective response rate (ORR) compared with irAEs‐non‐ILD patients and non‐irAEs patients (63%, 43% and 22%, respectively). Median progression‐free survival (mPFS) was 15.9 months in ILD patients, 5.4 months in irAEs‐non‐ILD patients and 3.3 months in non‐irAEs patients (log‐rank test, P = 0.033). Pre‐existing interstitial pneumonia (IP) was an independent risk factor for ILD‐induced ICIs (odds ratio [OR] 14.7; 95% confidence interval [CI]: 2.16–99.6, P = 0.006). Conclusions ORR and PFS were significantly better in ILD patients than in irAEs‐non‐ILD and non‐irAEs patients. Pre‐existing history of IP was an independent risk factor for ILD‐induced ICIs.

show abstract

“…Moreover, immunotherapy‐related thyroid dysfunction and dermatitis have been associated with a clinical benefit of ICIs in patients with nonsmall cell lung cancer . Moreover, pneumonitis has been associated with a clinical benefit . Further studies should investigate the relationship between pneumonitis and therapeutic effects in patients with RCC.…”

Section: Discussionmentioning

confidence: 86%

“…[17][18][19] Moreover, pneumonitis has been associated with a clinical benefit. 20 Further studies should investigate the relationship between pneumonitis and therapeutic effects in patients with RCC.…”

Section: Discussionmentioning

confidence: 99%

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Introduction A radiation recall reaction in previously irradiated lungs is known as radiation recall pneumonitis. We encountered a rare case of radiation recall pneumonitis induced by nivolumab 9 months after palliative radiotherapy to the ribs. Case presentation The patient was a 69‐year‐old woman with renal cell carcinoma. She had received various drugs and palliative irradiation, which was followed by nivolumab treatment, for renal cell carcinoma. Three days after the initial nivolumab administration, she presented with respiratory symptoms. On the basis of chest computed tomography findings, she was diagnosed with nivolumab‐induced radiation recall pneumonitis and treated with prednisolone (1 mg/kg). The condition resolved rapidly, and chest computed tomography 4 months after nivolumab cessation revealed interval resolution of the lung consolidation and persistent tumor shrinkage. Conclusion Physicians should consider the risk of radiation recall pneumonitis during treatment with immune checkpoint inhibitors in patients who have received previous thoracic radiotherapy.

show abstract

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Cited by 124 publications

References 27 publications

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma

Contact Info

Product

Resources

About